AbbVie Inc (BSP:ABBV34)
R$ 69.32 0 (0%) Market Cap: 1.97 Til Enterprise Value: 2.37 Til PE Ratio: 62.50 PB Ratio: 52.72 GF Score: 80/100

AbbVie Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 08:00PM GMT
Release Date Price: R$19.35
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

My name is Jason Gerberry. I'm the U.S. pharma analyst here at Bank of America. I'm pleased to be introducing AbbVie. I'm joined by Mike Severino, Vice Chairman and President; and Rob Michael, Chief Financial Officer. So gentlemen, thank you so much for joining us at our conference.

Michael E. Severino
AbbVie Inc. - Vice Chairman & President

Pleasure to be here.

Robert A. Michael
AbbVie Inc. - Senior VP & CFO

Thanks for having us.

Questions & Answers

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Yes. So in terms of the questions, it's probably not a surprise to focus on immunology and your hematology franchises and either your recent launches and your pipeline. So maybe we can start on the immunology side and your recent launch of SKYRIZI. I think as we think about this story, what probably caught a lot of the investors'

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot